Tirzepatide vs Semaglutide: Key Differences Explained

Tirzepatide and semaglutide are both incretin-based peptides. Semaglutide acts on one receptor (GLP-1). Tirzepatide acts on two (GIP and GLP-1). In one large head-to-head trial, tirzepatide produced greater average weight loss than semaglutide.

Both are FDA-approved prescription medicines. They are meant to be used under a doctor's care.

Kylo Peptides supplies research compounds for laboratory use only. Please read the Legal and FDA Status section below before you go further.

What Are Tirzepatide and Semaglutide?

Both are peptides. A peptide is a short chain of amino acids. Scientists study them to understand how hormone signals work.

Both belong to the incretin field. Incretins are gut hormones. They help control blood sugar and appetite signals.

They are among the most studied peptides in metabolic research today. That is why people often compare them.

How They Work: The Receptor Targets

A receptor is a docking point on a cell. A hormone fits into it like a key in a lock. When the key fits, the cell gets a signal.

GLP-1 receptor: linked to appetite and blood sugar signaling.
GIP receptor: linked to insulin response and fat tissue signaling.

Semaglutide switches on the GLP-1 receptor only. It is called a single agonist.

Tirzepatide switches on both the GLP-1 and the GIP receptors. It is called a dual agonist.

This is the core difference. It is the reason researchers want to know what the extra GIP signal adds.

Side-by-Side Comparison

Feature	Tirzepatide	Semaglutide
Receptor type	Dual agonist	Single agonist
GLP-1 receptor	Yes	Yes
GIP receptor	Yes	No
Drug class	Incretin-based peptide	Incretin-based peptide
FDA status	Approved prescription medicine	Approved prescription medicine
Main research interest	Added GIP pathway	Established GLP-1 model

What the Published Research Shows

The data below comes from human clinical trials. It is reported for information only. It is not a recommendation for any use.

The head-to-head trial

In 2025, the New England Journal of Medicine published the first direct trial of the two compounds. It was a 72-week study with 751 adults who had obesity or overweight and did not have diabetes.

Average weight loss was about 20.2% with tirzepatide. It was about 13.7% with semaglutide.

More people in the tirzepatide group also reached higher weight loss thresholds. For example, 31.6% lost at least 25% of body weight, compared with 16.1% in the semaglutide group.

What to keep in mind

This trial was open-label. That means participants and researchers knew which compound was used.

Results are averages. Individual results vary a lot. The trial also did not include people with diabetes.

The researchers reported a similar side effect pattern for both compounds.

Common Side Effects in Trials

Both compounds showed stomach-related side effects. These included nausea, diarrhea, vomiting and constipation.

These effects were most common when doses were being raised. They were often mild to moderate.

This is not a full safety profile. Anyone with health questions should talk to a licensed healthcare professional.

Why Researchers Compare Them

Semaglutide is the long-standing benchmark. It has a large body of published data. That makes it a useful reference compound.

Tirzepatide adds a second receptor target. It lets researchers ask a clear question: what does GIP signaling add on top of GLP-1?

Putting the two side by side shows how a small change in design can shift results. That is useful for anyone studying receptor pharmacology.

It also sets the stage for newer multi-receptor compounds. One example is retatrutide, which adds a third target. You can read more in our guide on retatrutide vs tirzepatide.

Key Differences at a Glance

Receptors: semaglutide has one target. Tirzepatide has two.
Head-to-head data: tirzepatide showed greater average weight loss in the one direct trial.
Research role: semaglutide is the benchmark. Tirzepatide is the next step in design.
Status: both are approved prescription medicines.

Legal and FDA Status

This is the most important section for any reader.

Both tirzepatide and semaglutide are FDA approved as prescription medicines. They are meant to be used under a doctor's care. Medical decisions belong with a licensed healthcare professional.

Research compounds sold by suppliers like Kylo Peptides are for laboratory research only. They are not for human use. They are not for animal use. They are not medicines, foods or supplements.

Laws on research chemicals differ by country and by state. It is your job to check the rules where you work. The FDA publishes information on approved and unapproved products. Check its website for the latest position.

Frequently Asked Questions

Is tirzepatide better than semaglutide?

In one head-to-head trial, tirzepatide produced greater average weight loss. That does not mean it is right for any one person. Medical choices belong with a doctor.

What is the main difference between them?

Semaglutide targets the GLP-1 receptor. Tirzepatide targets both the GLP-1 and GIP receptors.

Are both FDA approved?

Yes. Both are approved prescription medicines.

Why do researchers study both?

Semaglutide is the benchmark. Tirzepatide adds a second target. Comparing them helps explain what the extra receptor does.

What is a dual agonist?

A dual agonist switches on two receptors at once. Tirzepatide is an example.

Where can researchers find lab-grade peptides?

Researchers can browse Kylo Peptides for lab-use research compounds. Please read the Legal and FDA Status section first.

Final Thoughts

Tirzepatide and semaglutide are close relatives. Both are incretin-based peptides with large bodies of research.

The main difference is the extra GIP receptor in tirzepatide. That one change is why the comparison draws so much attention.

Disclaimer

This article is for educational and research purposes only. All products sold by Kylo Peptides are intended for in-vitro laboratory research use only. They are not for human or animal consumption.

No medical advice is given. Nothing here is meant to diagnose, treat, cure or prevent any disease. Talk to a licensed healthcare professional about any medical question.

Tirzepatide and semaglutide are FDA approved only as prescription medicines. Buyers are responsible for following all laws that apply where they live and work.

Sources and References

New England Journal of Medicine: head-to-head trial of tirzepatide and semaglutide in adults with obesity, 2025
U.S. Food and Drug Administration (FDA): drug approval information for tirzepatide and semaglutide
PubMed: indexed studies on tirzepatide and semaglutide
ClinicalTrials.gov: registrations for tirzepatide and semaglutide trials